Approval · Notice of Compliance 8250 · 2006
RISPERDAL CONSTA: Notice of Compliance 8250
Issued September 8, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8250
- Date
- September 8, 2006
- Company
- Janssen-Ortho Inc.
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of drug interaction information with topamax
- Therapeutic class
- Antipsychotic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RISPERDAL CONSTA | Not yet assigned | — |
| RISPERDAL CONSTA 3N | Not yet assigned | — |
Medicinal ingredients
- RISPERIDONE 25 MG per VIAL
- RISPERIDONE 37.5 MG per VIAL
- RISPERIDONE 50 MG per VIAL